SG11202108062PA - Novel bispecific antibody molecule and bispecific antibody simultaneously binding to pd-l1 and lag-3 - Google Patents

Novel bispecific antibody molecule and bispecific antibody simultaneously binding to pd-l1 and lag-3

Info

Publication number
SG11202108062PA
SG11202108062PA SG11202108062PA SG11202108062PA SG11202108062PA SG 11202108062P A SG11202108062P A SG 11202108062PA SG 11202108062P A SG11202108062P A SG 11202108062PA SG 11202108062P A SG11202108062P A SG 11202108062PA SG 11202108062P A SG11202108062P A SG 11202108062PA
Authority
SG
Singapore
Prior art keywords
bispecific antibody
lag
simultaneously binding
novel
antibody molecule
Prior art date
Application number
SG11202108062PA
Inventor
Haiqing Ni
Bingliang Chen
Junjian Liu
Original Assignee
Innovent Biologics Suzhou Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innovent Biologics Suzhou Co Ltd filed Critical Innovent Biologics Suzhou Co Ltd
Publication of SG11202108062PA publication Critical patent/SG11202108062PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202108062PA 2019-01-25 2020-01-23 Novel bispecific antibody molecule and bispecific antibody simultaneously binding to pd-l1 and lag-3 SG11202108062PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910073261 2019-01-25
PCT/CN2020/073964 WO2020151762A1 (en) 2019-01-25 2020-01-23 Novel bispecific antibody molecule and bispecific antibody simultaneously combining pd-l1 and lag-3

Publications (1)

Publication Number Publication Date
SG11202108062PA true SG11202108062PA (en) 2021-08-30

Family

ID=71735420

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202108062PA SG11202108062PA (en) 2019-01-25 2020-01-23 Novel bispecific antibody molecule and bispecific antibody simultaneously binding to pd-l1 and lag-3

Country Status (11)

Country Link
US (1) US20220112284A1 (en)
EP (1) EP3916016A4 (en)
JP (1) JP2022518519A (en)
KR (1) KR20210120008A (en)
CN (1) CN113383017B (en)
AU (1) AU2020212228A1 (en)
BR (1) BR112021014522A2 (en)
CA (1) CA3126881A1 (en)
SG (1) SG11202108062PA (en)
TW (1) TWI756621B (en)
WO (1) WO2020151762A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109970856B (en) 2017-12-27 2022-08-23 信达生物制药(苏州)有限公司 anti-LAG-3 antibodies and uses thereof
WO2022268168A1 (en) * 2021-06-23 2022-12-29 迈威(上海)生物科技股份有限公司 New type bispecific antibody targeting lag-3 and pd-l1 and use thereof
WO2023078450A1 (en) * 2021-11-05 2023-05-11 Vibrant Pharma Limited Multispecific antibodies and uses thereof
CN114478789B (en) * 2021-12-20 2024-06-14 安徽安科生物工程（集团）股份有限公司 Bispecific antibodies against PD-L1 and OX40 and uses thereof
CN117186223B (en) * 2022-05-31 2024-08-09 明济生物制药（北京）有限公司 Anti-PD-L1 antibody, nucleic acid encoding same, preparation method and application

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
JP4157160B2 (en) 1991-12-13 2008-09-24 ゾーマ テクノロジー リミテッド Methods for the preparation of modified antibody variable regions
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP1087013B1 (en) 1992-08-21 2009-01-07 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
SI1639011T1 (en) 2003-06-30 2009-04-30 Domantis Ltd Pegylated single domain antibodies (dAb)
JO3000B1 (en) 2004-10-20 2016-09-05 Genentech Inc Antibody Formulations.
CN104004088B (en) * 2007-09-26 2017-11-07 Ucb医药有限公司 dual specificity antibody fusions
PT2694549T (en) 2011-04-08 2018-11-22 Us Health Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
AU2012275390A1 (en) * 2011-06-28 2014-01-16 Whitehead Institute For Biomedical Research Using sortases to install click chemistry handles for protein ligation
TWI680138B (en) * 2014-01-23 2019-12-21 美商再生元醫藥公司 Human antibodies to pd-l1
BR122024001145A2 (en) * 2014-03-14 2024-02-27 Novartis Ag ISOLATED ANTIBODY MOLECULE CAPABLE OF BINDING TO LAG-3, ITS PRODUCTION METHOD, PHARMACEUTICAL COMPOSITION, NUCLEIC ACIDS, EXPRESSION VECTOR, METHOD FOR DETECTION OF LAG-3 IN A BIOLOGICAL SAMPLE, AND USE OF SAID ANTIBODY MOLECULE AND COMPOSITION
CN106188305A (en) * 2015-06-01 2016-12-07 中山大学 There is the bivalent antibody of the single domain Fab being fused to conventional Fab fragment
CN106432502B (en) * 2015-08-10 2020-10-27 中山大学 Bispecific nanobody for treating CEA positive expression tumor
KR20180086502A (en) * 2015-12-16 2018-07-31 머크 샤프 앤드 돔 코포레이션 The anti-LAG3 antibody and the antigen-binding fragment
SG11201809336QA (en) * 2016-05-09 2018-11-29 Igm Biosciences Inc Anti-pd-l1 antibodies
JP2019528082A (en) * 2016-06-08 2019-10-10 シャンハイ ジャオ トン ユニバーシティ スクール オブ メディシン Antibody heavy chain constant region sequences that enhance the activity of agonist antibodies
ES2858091T3 (en) * 2016-06-20 2021-09-29 F Star Therapeutics Ltd Binding molecules that bind to PD-L1 and LAG-3
WO2018014260A1 (en) * 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN107686520B (en) * 2016-08-04 2023-01-03 信达生物制药(苏州)有限公司 anti-PD-L1 nano antibody and application thereof
KR20200021474A (en) * 2017-06-01 2020-02-28 컴퓨젠 엘티디. Triple Combination Antibody Therapeutics
EP3652212A4 (en) * 2017-07-13 2021-04-14 Nanjing Leads Biolabs Co., Ltd. Antibodies binding lag-3 and uses thereof

Also Published As

Publication number Publication date
US20220112284A1 (en) 2022-04-14
EP3916016A4 (en) 2022-11-02
JP2022518519A (en) 2022-03-15
CA3126881A1 (en) 2020-07-30
EP3916016A1 (en) 2021-12-01
KR20210120008A (en) 2021-10-06
CN113383017B (en) 2023-04-28
TW202043277A (en) 2020-12-01
AU2020212228A1 (en) 2021-08-19
TWI756621B (en) 2022-03-01
BR112021014522A2 (en) 2021-11-30
CN113383017A (en) 2021-09-10
WO2020151762A1 (en) 2020-07-30

Similar Documents

Publication Publication Date Title
SG11202108062PA (en) Novel bispecific antibody molecule and bispecific antibody simultaneously binding to pd-l1 and lag-3
IL268527A (en) Bispecific antibodies specifically binding to pd1 and lag3
EP3875485A4 (en) Bispecific antibody binding to cd20 and cd3 and uses thereof
IL283939A (en) Antibodies binding to cd3
EP3720963A4 (en) Antigen-binding molecule comprising altered antibody variable region binding cd3 and cd137
IL287613A (en) Antibodies binding to gprc5d
DK3472207T3 (en) BINDING MOLECULES THAT BIND PD-L1 AND LAYER-3
EP3788079A4 (en) High affinity antibodies to pd-1 and lag-3 and bispecific binding proteins made therefrom
AU2016210068A1 (en) Anti-CD3 antibodies, anti-CD123 antibodies and bispecific antibodies specifically binding to CD3 and/or CD123
IL253569A0 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
IL281787A (en) Antigen-binding molecules capable of binding cd3 and cd137 but not simultaneously
IL264248A (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
IL280004A (en) Antibody molecules that bind pd-l1 and cd137
EP3816187A4 (en) Monoclonal antibody specifically binding to lag-3 and use thereof
GB2597851B (en) Antibody molecules that bind to NKP30 and uses thereof
IL288749A (en) Multispecific heavy chain antibodies binding to cd22 and cd3
EP3613770A4 (en) Monoclonal antibody to pd-l1
EP3998283A4 (en) Antibody binding specifically to b7-h3 and use thereof
SG11202101152QA (en) Antigen-binding molecule containing two antigen-binding domains that are linked to each other
EP3768727A4 (en) Novel bispecific pd-1/lag-3 antibody molecules
GB201912681D0 (en) Bispecific binding agent that binds to cd117/c-kit and cd3
EP3970743A4 (en) Bispecific antibody binding to cd40 and fap
EP3904387A4 (en) Monoclonal antibodies that bind specifically to human trbv9
EP3710482A4 (en) Compositions and methods for making and using bispecific antibodies
SG11202111441QA (en) Bispecific antibodies against pd-1 and lag-3